+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 25Years - 65Years
All Genders
ID07444398

Study of Vericiguat Added to Standard Treatment with Sacubitril-Valsartan in Adults Aged 25 to 65 With Decompensated Heart Failure

Led by Khawaja Danish Ali · Updated on 2026-03-02

130

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of Vericiguat compared to a placebo in patients with decompensated heart failure. This Phase 1 randomized study aims to understand how adding Vericiguat to standard medical therapy affects hospitalization rates, cardiovascular death, and side effects. Seventy patients meeting specific heart failure criteria will be enrolled from the emergency department after informed consent is obtained. Participants will be randomly assigned into two groups. One group will receive Vericiguat starting at 2.5 mg daily, with doses gradually increased to 10 mg as tolerated, alongside standard treatment with sacubitril-valsartan. The other group will receive only the standard treatment of sacubitril-valsartan. All patients will be followed in outpatient clinics for three months, during which doses will be adjusted based on blood pressure, symptoms, and clinical evaluations. Throughout the study, researchers will collect detailed patient histories and monitor outcomes including hospital admissions for heart failure, cardiovascular-related deaths, and any side effects experienced. Data will be carefully recorded during the three-month follow-up period to assess the safety and impact of combining Vericiguat with standard therapy in decompensated heart failure patients.

CONDITIONS

Brief Title

Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

Research Team

D

Dr Khawaja Danish Ali, MBBS

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here